European Psychiatry - Volume 41 - April 2017

394 / 916

S390 25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404
ment Questionnaire, Internalized Stigma of Mental Illness Scale,
Temperament and Character Inventory, Adult Dispositional Hope
Scale, Drug Attitude Inventory, Liebowitz Social Anxiety Scale, Beck
Depression Inventory – II, and Beck Anxiety Inventory.
Results The quality of life was significantly higher in employed
patients, and individuals with higher hope, self-directedness, and
persistence. The quality of life was lower among the patients with
higher number of hospitalizations, thosewith higher severity of the
disorder and individuals who were taking more medication. The
patients with more pronounced symptoms of depression, anxiety,
and social anxiety had a lower quality of life. Finally, the quality of
life was lower among the individuals with higher harm avoidance,
and self-stigmatization.
Conclusions Detection of the quality of life in the context of per-
sonality traits, hope, self-stigma and demographical and clinical
factors may be an important part of the treatment of patients with
schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0823
Negative aspects of self-stigma in
patients with schizophrenia spectrum
disorders
K. Vrbova ∗, J. Prasko , M. Ociskova , M. Holubova ,
D. Kamaradova , M. Marackova , A. Grambal , M. Slepecky ,
K. Latalova
1 Faculty of Medicine and Dentistry, Palacky University and
University Hospital Olomouc, Department of Psychiatry, Olomouc,
Czech Republic
2 Faculty of Medicine and Dentistry, Palacky University and
University Hospital Olomouc, Hospital Liberec, Department of
Psychiatry, Olomouc, Liberec, Czech Republic
3 Faculty of Social Science and Health Care, Constantine the
Philosopher University in Nitra, Department of Psychology Sciences,
Nitra, Slovak Republic
∗ Corresponding author.
Introduction Most individuals diagnosed with schizophrenia
must cope with some form of stigmatization. Different types of
public stigma, self-stigma and label avoidance, may have negative
consequences for these individuals.
Objectives The aim of the study was to search the degree of self-
stigma in schizophrenia and its association with the clinical and
demographic factors.
Methods One hundred and ninety-seven stabilized outpatients
diagnosed with schizophrenia spectrum disorders participated
in the study. The mean age of the sample was 40 years. All
individuals completed the Internalized Stigma of Mental Illness
Scale (ISMI) and a demographic questionnaire. The disorder sever-
ity was assessed both by a psychiatrist (objCGI-S: the objective
version of Clinical Global Impression – Severity scale) and by
the patients (subjCGI-S: the subjective version of Clinical Global
Impression – Severity scale).
Results The total score of the ISMI positively correlated with
the severity of the disorder measured by the objCGI-S and the
subjCGI-S. Additionally, the self-stigma positively correlated with
the treatment duration, and the number of hospitalizations. The
regression analysis identified these regressors as the most relevant
to the self-stigma – the number of hospitalizations, the severity
of the disorder rated by a psychiatrist, and the difference between
the objective rating and the subjective rating of the severity of the
disorder.
Conclusions Outpatients with psychosis, who have undergone a
higher number of hospitalizations, dispose of a higher severity of
the disorder and show a bigger discrepancy between their rating of
the severity and the psychiatric rating, display a greater degree of
self-stigma.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0824
Therapy initiation during a first acute
episode psychosis in the psychiatric
department of Mahdia
B. Walid ∗ arrag , R. Ben Soussia , F. Ellouze , M. Nasr
Hospital, Psychiatrie, Mahdia, Tunisia
∗ Corresponding author.
Introduction The quality of the therapeutic care during a first
episode psychosis (FEP) determines the middle- and long-term
prognosis.
Objectives The aim of our study is to describe the therapeutic
attitudes in front of a FEP and discuss them according to current
international recommendations.
Methods This is a retrospective descriptive study. All patients
with a FEP, hospitalized in the psychiatric department of the uni-
versity hospital, Mahdia during the period from 15 May 2000 to 31
December 2013 have been included.
Results We recruited 111 patients. The average age was 27
years, a male predominance was noted. Initially, the majority of
patients were treated in monotherapy (55.9%) and mostly with
typical antipsychotic drugs (80.2%), by injection. Among those
under association, 63.4% received corrective treatment and 26.8%
a benzodiazepine. The prescription of a mood stabilizer and an
antidepressant was noted in respectively 5.6 and 2.8% of cases. The
majority of patients received typical antipsychotic drugs (53.1%)
while 39.6% were under atypical antipsychotic. The follow-up
period, after which a reduction of the antipsychotic dose was
decided, ranged from 1 to 66 months with an average of 8.26.
Conclusion The progression to a chronic psychosis, still has a
severe connotation. The Early and adequate therapeutic care in
accordance with the international recommendations, determines
the prognosis and constitute a decisivemoment in the evolutionary
trajectory of the disease.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0825
Effectiveness of health checks to
improve the physical health of people
with severe mental illness in
secondary care: A single blind cluster
randomised controlled trial
J. White ∗, J. Lucas , L. Swift , G. Barton , G. Harriet , L. Irvine ,
G. Abotsie , M. Jones , R. Gray
1 University of Hull, Faculty of Health and Social Care, Hull, United
Kingdom
2 James Paget University Hospitals NHS Foundation Trust, Research
and Development, Great Yarmouth, United Kingdom
3 University of East Anglia, Norwich Medical School, Norwich, United
Kingdom
4 University of East Anglia, Clinical Trials Unit, Norwich, United
Kingdom
5 University of East Anglia, School of Psychology, Norwich, United
Kingdom
6 University of East Anglia, Clinical Trial Unit, Norwich, United
Kingdom
7 Norfolk and Suffolk NHS Foundation Trust, Research and
Development, Norwich, United Kingdom